Study Evaluating the Efficacy of a Reduced Dose Atazanavir in HIV-1-infected Patients

PHASE2CompletedINTERVENTIONAL
Enrollment

90

Participants

Timeline

Start Date

June 30, 2015

Primary Completion Date

December 31, 2017

Study Completion Date

December 31, 2017

Conditions
HIV-1 Infection
Interventions
DRUG

Atazanavir 200 mg/r

"1. In patients signed an informed consent and meeting all the eligibility criteria at the time of the run-in (S-4),~2. switch of antiretroviral therapy Atazanavir 300 mg/ritonavir 100 mg once a day to Atazanavir 200 mg/ritonavir 100 mg once a day without changing the combination of 2 NRTIs associated.~The administration will be done once a day orally for 48 weeks.~The usual recommended dose of atazanavir is 300 mg once daily with 100 mg of ritonavir once daily with food. Ritonavir acts by potentiating the pharmacokinetics of atazanavir."

Trial Locations (1)

75013

DUDOIT Yasmine, Paris

All Listed Sponsors
collaborator

INSERM UMR S 1136

OTHER

lead

Centre de Recherches et d'Etude sur la Pathologie Tropicale et le Sida

OTHER

NCT02473328 - Study Evaluating the Efficacy of a Reduced Dose Atazanavir in HIV-1-infected Patients | Biotech Hunter | Biotech Hunter